Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
DOI10.1080/01621459.2014.926815zbMATH Open1373.62547OpenAlexW2137499396WikidataQ40543401 ScholiaQ40543401MaRDI QIDQ5367394FDOQ5367394
Authors: Juhee Lee, Peter F. Thall, Yuan Ji, P. Müller 
Publication date: 13 October 2017
Published in: Journal of the American Statistical Association (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc4562700
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Adaptive designs for dose-finding based on efficacy-toxicity response
Bayesian designQ-learningadaptive designdynamic treatment regimephase I-II clinical trialevaluation of robustnesslatent probit model
Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Robustness and adaptive procedures (parametric inference) (62F35)
Cited In (26)
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
- A Bayesian phase I/II clinical trial design in the presence of informative dropouts
- A utility approach to individualized optimal dose selection using biomarkers
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- A Bayesian machine learning approach for optimizing dynamic treatment regimes
- Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
- Estimating individualized treatment rules with risk constraint
- uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Adaptive Bayesian compound designs for dose finding studies
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
- Controlling Cumulative Adverse Risk in Learning Optimal Dynamic Treatment Regimens
- Title not available (Why is that?)
- A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Sequential multiple assignment randomized trial (SMART) with adaptive randomization for quality improvement in depression treatment program
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Modeling heterogeneity in the assessment of treatment effects on tumor development while accounting for monotone dropout
- Optimal Treatment Regimes: A Review and Empirical Comparison
This page was built for publication: Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5367394)
